A PHASE 1, RANDOMIZED, OPEN-LABEL, 3-PERIOD, 4-SEQUENCE, CROSSOVER, SINGLE-DOSE STUDY TO COMPARE THE BIOAVAILABILITY OF ORALLY ADMINISTERED BOSUTINIB CAPSULES AND TO ESTIMATE THE EFFECT OF FOOD ON BOSUTINIB CAPSULE
Latest Information Update: 12 Jul 2022
At a glance
- Drugs Bosutinib (Primary)
- Indications Chronic myeloid leukaemia; Glioblastoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacokinetics
- Sponsors Pfizer
- 06 Jul 2022 Status changed from active, no longer recruiting to completed.
- 24 May 2022 Status changed from recruiting to active, no longer recruiting.
- 08 Feb 2022 Planned End Date changed from 1 Jul 2022 to 22 Jun 2022.